The aim of this study was to analyze the efficacy of first-line
chemotherapy in treating patients with ocular adnexal extranodal
marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT). Eight consecutive newly diagnosed ocular adnexal
MALT lymphoma patients were treated with
chemotherapy, in which 3 patients in stage IE were treated with a combination of
cyclophosphamide,
vincristine and
prednisolone (COP) or
cyclophosphamide,
adriamycin,
vincristine, and
prednisolone (CHOP), 5 patients in stage IV were treated with COP/CHOP in combination with
rituximab. The results showed that
chemotherapy resulted in an overall response rate of 100%, 3 patients in stage IE were in partial remission (PR), 5 patients in stage IV were
in complete remission (CR). After a median follow-up of 21 months, 3 patients in stage IE were still in PR status, 5 patients in stage IV were still in CR status, and no relapses or
disease progression were observed. It is concluded that the first-line
chemotherapy has been confirmed to be effective and well tolerated in patients with localized ocular adnexal
MALT lymphoma.
Rituximab combined with
chemotherapy can increase remission rate, it is feasible option as first-line treatment for ocular adnexal
MALT lymphoma.